Displaying drugs 1126 - 1150 of 2534 in total
ORE-1001
ORE1001 has been used in trials studying the treatment of Mild to Moderate Ulcerative Colitis. It is an ACE2 inhibitor.
Investigational
NCX-1000
NCX-1000 is under investigation in clinical trial NCT00414869 (Preliminary Efficacy and Tolerability of NCX-1000 After Repeated Oral Doses in Patients With Elevated Portal Pressure).
Investigational
DRF-1042
Investigational
Matched Iupac: … (19S)-19-ethyl-19-hydroxy-12-(2-hydroxyethoxy)-17-oxa-3,13-diazapentacyclo[11.8.0.0^{2,11}.0^{4,9}.0^ …
G100
Investigational
KAHR-102
KAHR-102 is a dual signaling protein fusing cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) to the Fas-ligand (FasL).
Investigational
TSHA-104
Investigational
IBIO-100
IBIO-100 is a high molecular weight multimer of E3-Fc, an endostatin C-terminus and IgG1-Fc fusion protein.
Investigational
TSHA-101
Investigational
Matched Synonyms: … adeno-associated viral vector serotype 9 (AAV9) carrying both HEXA and HEXB …
MDX-1097
MDX-1097 is a chimeric monoclonal antibody directed against the kappa myeloma antigen (KMA).
Investigational
TSHA-102
TSHA-102 is a recombinant serotype 9 adeno-associated virus encoding a codon-optimized human MECP2 gene.
Investigational
Matched Description: … TSHA-102 is a recombinant serotype 9 adeno-associated virus encoding a codon-optimized human MECP2 gene …
AOC-1020
AOC-1020 is an antibody oligonucleotide conjugate, comprised of a human transferrin receptor 1 targeting, effector function null, humanized IgG1 antibody, a MCC maleimide linker, and a double-stranded siRNA oligonucleotide targeting DUX4.
Investigational
Lumicitabine
Lumicitabine is under investigation in clinical trial NCT03010059 (A Study to Assess the Relative Bioavailability of JNJ64041575 Administered as 2 Different New Concept Formulations (Oral Suspension and Tablet) Compared to Their Respective Current Formulations, and to Assess the Effect of Food on the Pharmacokinetics of the 2 New Concept Formulations).
Investigational
FG-9041
Experimental
MLN-977
MLN-977 is a small molecule compound that inhibits the production of leukotrienes, especially 5-lipoxygenase. It is developed by PharmaEngine to treat asthma and chronic obstructive pulmonary disease.
Investigational
AVN-944
AVN944 is a biotech drug that demonstrated a statistically meaningful impact on IMPDH and other proteins that are critical to activities in cancer cells, including nucleotide biosynthesis, energy and metabolism, DNA replication, apoptosis and cell cycle control. AVN944 has been associated with cancer cell death in clinical trials. It is...
Investigational
TNX-901
TNX-901 is a therapeutic monoclonal antibodies designed to address significant unmet medical needs in the areas of asthma, allergy, inflammation and other diseases affecting the human immune system.
Investigational
CPD 923
CPD 923 (N-butylgalactonorjirimycin) is an iminosugar and an analogue of ZavescaTM. It shows efficacy in vivo studies, as well as a favourable pre-clinical tolerability profile.
Investigational
WNT-974
WNT974 has been used in trials studying the treatment of Metastatic Colorectal Cancer and Squamous Cell Carcinoma, Head And Neck.
Investigational
ATX-914
Axt914 is under investigation in clinical trial NCT00417261 (Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of Single and Multiple-Doses of ATF936 and AXT914 Administered Orally in Healthy Subjects.).
Investigational
CRA_10433
Experimental
Displaying drugs 1126 - 1150 of 2534 in total